Analyzing the impact of Medicare Part D for Oncology Patients
By Xcenda |
Celgene Corporation commissioned Xcenda to analyze the impact of the Medicare prescription benefit (Part D) for oncology patients. Xcenda’s research and analysis showed that Medicare patients utilizing Part D for their oncology care are, on average, less expensive and use fewer medical services than expected.
Xcenda Original Research: Part D Reduces Medical Costs and Improves Access for Oncology Patients
Key study findings include:
- Prescriptions available to cancer patients through the Part D program have delivered greater savings to the Medicare program than estimated by the Congressional Budget Office (CBO)
- Patients utilizing only Part D for their treatment used fewer inpatient services, outpatient services, and physician services
- In 2013, medical costs for oncology patients receiving treatment under Part D only were 58% lower than what the CBO had estimated for this population ($17,831 vs $42,606)